According to Zhitong Finance App News, Tengsheng Pharmaceutical-B (02137.HK) announced the end of treatment (EOT) and follow-up results of its Phase IIb ENRICITY and ENHANCE study in the form of three latest breakthrough reports at the American Society for Liver Disease Research (AASLD) Liver Disease Annual Meeting® held in Denver, Colorado, USA from November 5 to 9, 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.